Generic placeholder image

Current Pharmaceutical Design

Author(s): Bei Wang, Wen Xu, Yuxuan Cai, Chong Guo, Gang Zhou and Chengfu Yuan*

DOI: 10.2174/1381612826666200922153701

DownloadDownload PDF Flyer Cite As
CASC15: A Tumor-Associated Long Non-Coding RNA

Page: [127 - 134] Pages: 8

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: CASC15, one of long non-coding RNA, is involved in the regulation of many tumor biological processes, and is expected to become a new biological therapeutic target. This paper aims to elucidate the pathophysiological function of CASC15 in various tumors.

Methods: The relationship between CASC15 and tumors was analyzed by searching references, and summarized the specific pathophysiological mechanism of CASC15.

Results: LncRNA CASC15 is closely related to tumor development, and has been shown to be abnormally high expressed in all kinds of tumors, including breast cancer, cervical cancer, lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, colon cancer, colorectal cancer, cardiac hypertrophy, intrahepatic cholangiocarcinoma, leukemia, melanoma, tongue squamous cell carcinoma and nasopharyngeal carcinoma. However, CASC15 has been found to be down-expressed abnormally in ovarian cancer, glioma and neuroblastoma. Besides, it is identified that CASC15 can affect the proliferation, invasion and apoptosis of tumors.

Conclusion: LncRNA CASC15 has the potential to become a new therapeutic target or marker for a variety of tumors.

Keywords: Long non-coding RNA, CASC15, malignancy, biomarker, molecular mechanism, therapeutic target.

[1]
Fernando TR, Contreras JR, Zampini M, et al. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Mol Cancer 2017; 16(1): 126.
[http://dx.doi.org/10.1186/s12943-017-0692-x] [PMID: 28724437]
[2]
Biochemical, br communications, LncRNA cancer susceptibility candidate 15 accelerates the breast cancer cells progression via miR-153-3p/KLF5 positive feedback loop 2018; 506: 819-25.
[3]
Shan S, Li HF, Yang XY, et al. Higher lncRNA CASC15 expression predicts poor prognosis and associates with tumor growth in cervical cancer. Eur Rev Med Pharmacol Sci 2019; 23(2): 507-12.
[PMID: 30720157]
[4]
OncoTargets, therapy, Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis 2018; 11: 4877-91.
[5]
Yu X, Wang ZL, Han CL, et al. LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer. Eur Rev Med Pharmacol Sci 2019; 23(22): 9814-20.
[PMID: 31799648]
[6]
Mm reports, LncRNA CASC15 promotes colon cancer cell proliferation and metastasis by regulating the miR‑4310/LGR5/Wnt/β‑catenin signaling pathway 2018; 18: 2269-76.
[7]
Gao R, Fang C, Xu J, Tan H, Li P, Ma L. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch Biochem Biophys 2019; 663: 183-91.
[http://dx.doi.org/10.1016/j.abb.2019.01.005] [PMID: 30639170]
[8]
Long noncoding RNA CASC15 is upregulated in non-small cell lung cancer and facilitates cell proliferation and metastasis via targeting miR-130b-3p Eur Rev Med Pharmacol Sci 2019; 23: 7943-9.
[9]
WJIjo oncology, Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis Int J Oncol 2017; 51: 1722-30.
[10]
Li C, Zhou G, Feng J, Zhang J, Hou L, Cheng Z. Upregulation of lncRNA VDR/CASC15 induced by facilitates cardiac hypertrophy through modulating miR-432-5p/TLR4 axis. Biochem Biophys Res Commun 2018; 503(4): 2407-14.
[http://dx.doi.org/10.1016/j.bbrc.2018.06.169] [PMID: 29966657]
[11]
Merdrignac A, Angenard G, Allain C, et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol Commun 2018; 2(3): 254-69.
[http://dx.doi.org/10.1002/hep4.1142] [PMID: 29507901]
[12]
Yin Y, Zhao B, Li D, Yin G. Long non-coding RNA CASC15 promotes melanoma progression by epigenetically regulating PDCD4. Cell Biosci 2018; 8: 42.
[http://dx.doi.org/10.1186/s13578-018-0240-4] [PMID: 30013768]
[13]
Wu X, Ma J, Chen J, Huang H. LncRNA CACS15 regulates tongue squamous cell carcinoma cell behaviors and predicts survival. BMC Oral Health 2019; 19(1): 231.
[http://dx.doi.org/10.1186/s12903-019-0924-0] [PMID: 31665008]
[14]
Biology, Medicine, Long-noncoding RNAs in basal cell carcinoma 2016; 37: 10595-608.
[15]
CHJErf medical, p sciences, Long non-coding RNA CASC15 promotes nasopharyngeal carcinoma cell proliferation and metastasis by downregulating miR-101-3p 2019; 23: 8897-904.
[16]
Xing Y, Wen X, Ding X, et al. CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma 2017; 25: 1209-21.
[17]
Ni H, Chai P, Yu J, et al. disease, LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter 2020; 11: 306.
[18]
Zhang X, Guo B, Zhu Y, Xu W, Ning S, Liu L. Up-regulation of plasma lncRNA CACS15 distinguished early-stage oral squamous cell carcinoma patient. Oral Dis 2019.
[http://dx.doi.org/10.1111/odi.13245] [PMID: 31793142]
[19]
Gao Z, Xiong Z, Sun Y, et al. CASC15 polymorphisms are correlated with cervical cancer susceptibility in Chinese women. Mol Genet Genomic Med 2020; 8(6)e1246
[http://dx.doi.org/10.1002/mgg3.1246] [PMID: 32329235]
[20]
Zhang YN, Liu B, Jiang T, Li Q. Long non-coding RNA CASC15 promotes proliferation and induces apoptosis of cervical cancer cells through targeting miR-101-3p. Eur Rev Med Pharmacol Sci 2020; 24(2): 611-8.
[PMID: 32016962]
[21]
C Y, Z J, G Z, W T, ZPJAjot research, Long noncoding RNA CASC15 predicts unfavorable prognosis and exerts oncogenic functions in non-small cell lung cancer 2019; 11: 4303-14.
[22]
Bai Y, Zhang G, Cheng R, Yang R, Chu H. CASC15 contributes to proliferation and invasion through regulating miR-766-5p/ KLK12 axis in lung cancer. Cell Cycle 2019; 18(18): 2323-31.
[http://dx.doi.org/10.1080/15384101.2019.1646562] [PMID: 31378128]
[23]
T JH, Z H, JYJErf medical, p sciences, High expression of LncRNA CASC15 is a risk factor for gastric cancer prognosis and promote the proliferation of gastric cancer 2017.
[24]
X S, M J, H P, W T, M W, S M, WYJM oncology, Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1 2018.
[25]
C G, Y Y, FQJEjo pharmacology, CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging 2019; 860: 172589.
[26]
Wang C, Zi H, Wang Y, Li B, Ge Z, Ren X. LncRNA CASC15 promotes tumour progression through SOX4/Wnt/β-catenin signalling pathway in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2020; 48(1): 763-9.
[http://dx.doi.org/10.1080/21691401.2019.1576713] [PMID: 32285705]
[27]
He T, Zhang L, Kong Y, et al. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. Int J Oncol 2017; 51(6): 1722-30.
[http://dx.doi.org/10.3892/ijo.2017.4175] [PMID: 29075788]
[28]
Zhu X, Wang D, Lin Q, et al. Screening key lncRNAs for human rectal adenocarcinoma based on lncRNA-mRNA functional synergistic network. Cancer Med 2019; 8(8): 3875-91.
[http://dx.doi.org/10.1002/cam4.2236] [PMID: 31116002]
[29]
Liu H, Gu X, Wang G, et al. Copy number variations primed lncRNAs deregulation contribute to poor prognosis in colorectal cancer. Aging (Albany NY) 2019; 11(16): 6089-108.
[http://dx.doi.org/10.18632/aging.102168] [PMID: 31442207]
[30]
Zhang C, Wang GX, Fu B, Zhou XC, Li Y, Li YY. LncRNA CASC15 promotes migration and invasion in prostate cancer via targeting miR-200a-3p. Eur Rev Med Pharmacol Sci 2019; 23(19): 8303-9.
[PMID: 31646560]
[31]
Hitte C, Le Béguec C, Cadieu E, et al. Genome-Wide Analysis of Long Non-Coding RNA Profiles in Canine Oral Melanomas. Genes (Basel) 2019; 10(6): 477.
[http://dx.doi.org/10.3390/genes10060477] [PMID: 31234577]
[32]
Lessard L, Liu M, Marzese DM, et al. The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. J Invest Dermatol 2015; 135(10): 2464-74.
[http://dx.doi.org/10.1038/jid.2015.200] [PMID: 26016895]
[33]
Sheng L, Wei R. Long Non-Coding RNA-CASC15 Promotes Cell Proliferation, Migration, and Invasion by Activating Wnt/beta-Catenin Signaling Pathway in Melanoma, Pathobiology : journal of immunopathology, molecular and cellular biology 2019; 1-10.
[34]
Zuo Z, Ma L, Gong Z, Xue L, Wang Q. Long non-coding RNA CASC15 promotes tongue squamous carcinoma progression through targeting miR-33a-5p. Environ Sci Pollut Res Int 2018; 25(22): 22205-12.
[http://dx.doi.org/10.1007/s11356-018-2300-z] [PMID: 29804249]
[35]
Cicek MS, Koestler DC, Fridley BL, et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet 2013; 22(15): 3038-47.
[http://dx.doi.org/10.1093/hmg/ddt160] [PMID: 23571109]
[36]
Martini P, Paracchini L, Caratti G, et al. Romualdi, lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study, Clinical cancer research : an official journal of the American Association for Cancer Research 2017; 23: 2356-66.
[37]
Shi Y, Gao S, Zheng Y, Yao M, Ruan F. LncRNA CASC15 Functions As An Unfavorable Predictor Of Ovarian Cancer Prognosis And Inhibits Tumor Progression Through Regulation Of miR-221/ARID1A Axis. OncoTargets Ther 2019; 12: 8725-36.
[http://dx.doi.org/10.2147/OTT.S219900] [PMID: 31695430]
[38]
Li Q, Liu W, Li S, Zhang S. Long non-coding RNA CASC15 favors tumorigenesis and development of ovarian cancer via sponging miR-542-3p. Panminerva Med 2019.
[PMID: 31355601]
[39]
Xie Y, Cheng Y. Long noncoding RNA CASC15 is upregulated in glioma and facilitates cell proliferation and metastasis via targeting miR-130b-3p. Eur Rev Med Pharmacol Sci 2019; 23(17): 7475-81.
[PMID: 31539135]
[40]
Mondal T, Kanduri C. LncRNAs join hands together to regulate neuroblastoma progression. Mol Cell Oncol 2018; 6(1)1553697
[http://dx.doi.org/10.1080/23723556.2018.1553697] [PMID: 30788421]
[41]
Mondal T, Juvvuna PK, Kirkeby A, et al. Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis. Cancer Cell 2018; 33(3): 417-434.e7.
[http://dx.doi.org/10.1016/j.ccell.2018.01.020] [PMID: 29533783]
[42]
Zhang J, Zhuo ZJ, Wang J, et al. CASC15 gene polymorphisms reduce neuroblastoma risk in Chinese children. Oncotarget 2017; 8(53): 91343-9.
[http://dx.doi.org/10.18632/oncotarget.20514] [PMID: 29207648]
[43]
Capasso M, Diskin SJ, Totaro F, et al. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis 2013; 34(3): 605-11.
[http://dx.doi.org/10.1093/carcin/bgs380] [PMID: 23222812]
[44]
Russell MR, Penikis A, Oldridge DA, et al. CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res 2015; 75(15): 3155-66.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-3613] [PMID: 26100672]
[45]
Prajapati B, Fatma M, Fatima M, Khan MT, Sinha S, Seth PK. Identification of lncRNAs Associated With Neuroblastoma in Cross-Sectional Databases: Potential Biomarkers. Front Mol Neurosci 2019; 12: 293.
[http://dx.doi.org/10.3389/fnmol.2019.00293] [PMID: 31920530]
[46]
Ni H, Chai P, Yu J, et al. LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter. Cell Death Dis 2020; 11(5): 306.
[http://dx.doi.org/10.1038/s41419-020-2524-y] [PMID: 32366932]
[47]
Xing Y, Wen X, Ding X, et al. CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma, Molecular therapy : the journal of the American Society of Gene Therapy 2017; 25: 1209-21.